Calumet Ebitda vs Total Operating Expenses Analysis

CLMT Stock

USD 22.54 0.14 0.63%

Calumet Specialty financial indicator trend analysis is way more than just evaluating Calumet Specialty prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Calumet Specialty is a good investment. Please check the relationship between Calumet Specialty Ebitda and its Total Operating Expenses accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calumet Specialty Products. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Ebitda vs Total Operating Expenses

Ebitda vs Total Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Calumet Specialty Ebitda account and Total Operating Expenses. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Calumet Specialty's Ebitda and Total Operating Expenses is 0.12. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of Calumet Specialty Products, assuming nothing else is changed. The correlation between historical values of Calumet Specialty's Ebitda and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of Calumet Specialty Products are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Ebitda i.e., Calumet Specialty's Ebitda and Total Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.12

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Ebitda

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most indicators from Calumet Specialty's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Calumet Specialty current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calumet Specialty Products. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

At this time, Calumet Specialty's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 2.1 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop 6.02 in 2024.

	2021	2022	2024 (projected)
Gross Profit	142.9M	350.8M	315.1M
Total Revenue	3.1B	4.7B	3.1B

Gross Profit Total Revenue

Calumet Specialty fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Other Current Liab	Total Current Liabilities	Accounts Payable	Other Liab	Cash	Long Term Debt	Inventory	Other Current Assets	Intangible Assets	Property Plant Equipment	Short Long Term Debt Total	Current Deferred Revenue	Net Debt	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total
Total Assets		0.24	0.93	0.96	0.58	-0.2	0.79	-0.19	0.81	0.51	0.21	0.48	0.85	0.11	0.14	0.83	0.72	0.02	0.64	0.93	0.79	0.23	0.8	0.03	0.84	0.81
Total Stockholder Equity	0.24		0.01	0.17	-0.17	-0.14	-0.12	0.57	-0.3	-0.42	-0.77	-0.56	0.33	-0.63	0.04	-0.18	0.54	-0.68	0.75	0.02	-0.3	-0.49	-0.27	0.11	0.18	-0.23
Property Plant And Equipment Net	0.93	0.01		0.97	0.56	-0.1	0.81	-0.29	0.88	0.61	0.35	0.52	0.75	0.23	-0.05	0.9	0.56	0.14	0.47	0.99	0.86	0.29	0.88	-0.17	0.64	0.89
Non Current Assets Total	0.96	0.17	0.97		0.58	-0.11	0.8	-0.24	0.82	0.55	0.24	0.44	0.79	0.15	-0.01	0.87	0.62	0.04	0.63	0.97	0.81	0.24	0.84	-0.14	0.7	0.86
Non Currrent Assets Other	0.58	-0.17	0.56	0.58		0.1	0.56	-0.26	0.61	0.69	0.69	0.76	0.68	0.78	-0.12	0.47	0.54	0.52	0.05	0.57	0.48	0.82	0.49	-0.21	0.57	0.53
Other Assets	-0.2	-0.14	-0.1	-0.11	0.1		-0.34	-0.05	-0.03	-0.1	0.04	-0.04	-0.06	0.23	-0.43	-0.1	-0.18	0.19	-0.12	-0.08	-0.1	0.29	-0.07	-0.47	-0.18	-0.06
Common Stock Shares Outstanding	0.79	-0.12	0.81	0.8	0.56	-0.34		-0.18	0.88	0.44	0.37	0.53	0.56	0.22	0.35	0.87	0.37	0.03	0.29	0.78	0.85	0.34	0.85	0.22	0.61	0.88
Other Stockholder Equity	-0.19	0.57	-0.29	-0.24	-0.26	-0.05	-0.18		-0.34	-0.68	-0.69	-0.54	-0.04	-0.45	0.03	-0.34	0.05	-0.8	0.07	-0.3	-0.39	-0.22	-0.36	0.2	-0.11	-0.34
Total Liab	0.81	-0.3	0.88	0.82	0.61	-0.03	0.88	-0.34		0.55	0.54	0.71	0.62	0.4	0.16	0.92	0.34	0.24	0.18	0.86	0.95	0.5	0.95	0.02	0.68	0.94
Property Plant And Equipment Gross	0.51	-0.42	0.61	0.55	0.69	-0.1	0.44	-0.68	0.55		0.79	0.73	0.4	0.69	-0.24	0.56	0.31	0.76	0.01	0.65	0.59	0.56	0.59	-0.34	0.44	0.57
Other Current Liab	0.21	-0.77	0.35	0.24	0.69	0.04	0.37	-0.69	0.54	0.79		0.9	0.23	0.91	-0.09	0.36	0.05	0.89	-0.46	0.36	0.45	0.75	0.42	-0.2	0.21	0.41
Total Current Liabilities	0.48	-0.56	0.52	0.44	0.76	-0.04	0.53	-0.54	0.71	0.73	0.9		0.52	0.82	-0.01	0.49	0.28	0.7	-0.25	0.52	0.58	0.79	0.57	-0.11	0.51	0.54
Accounts Payable	0.85	0.33	0.75	0.79	0.68	-0.06	0.56	-0.04	0.62	0.4	0.23	0.52		0.29	-0.1	0.51	0.9	0.08	0.48	0.74	0.47	0.35	0.5	-0.14	0.77	0.52
Other Liab	0.11	-0.63	0.23	0.15	0.78	0.23	0.22	-0.45	0.4	0.69	0.91	0.82	0.29		-0.34	0.17	0.15	0.82	-0.49	0.25	0.25	0.9	0.25	-0.4	0.17	0.24
Cash	0.14	0.04	-0.05	-0.01	-0.12	-0.43	0.35	0.03	0.16	-0.24	-0.09	-0.01	-0.1	-0.34		0.19	-0.08	-0.22	0.08	-0.07	0.21	-0.24	0.13	0.96	0.22	0.16
Long Term Debt	0.83	-0.18	0.9	0.87	0.47	-0.1	0.87	-0.34	0.92	0.56	0.36	0.49	0.51	0.17	0.19		0.27	0.11	0.38	0.9	0.98	0.28	0.98	0.04	0.65	0.99
Inventory	0.72	0.54	0.56	0.62	0.54	-0.18	0.37	0.05	0.34	0.31	0.05	0.28	0.9	0.15	-0.08	0.27		0.03	0.53	0.57	0.2	0.14	0.22	-0.08	0.63	0.26
Other Current Assets	0.02	-0.68	0.14	0.04	0.52	0.19	0.03	-0.8	0.24	0.76	0.89	0.7	0.08	0.82	-0.22	0.11	0.03		-0.44	0.17	0.2	0.57	0.16	-0.3	0.06	0.14
Intangible Assets	0.64	0.75	0.47	0.63	0.05	-0.12	0.29	0.07	0.18	0.01	-0.46	-0.25	0.48	-0.49	0.08	0.38	0.53	-0.44		0.48	0.26	-0.33	0.29	-0.01	0.45	0.33
Property Plant Equipment	0.93	0.02	0.99	0.97	0.57	-0.08	0.78	-0.3	0.86	0.65	0.36	0.52	0.74	0.25	-0.07	0.9	0.57	0.17	0.48		0.86	0.31	0.88	-0.18	0.66	0.89
Short Long Term Debt Total	0.79	-0.3	0.86	0.81	0.48	-0.1	0.85	-0.39	0.95	0.59	0.45	0.58	0.47	0.25	0.21	0.98	0.2	0.2	0.26	0.86		0.37	0.99	0.06	0.67	0.98
Current Deferred Revenue	0.23	-0.49	0.29	0.24	0.82	0.29	0.34	-0.22	0.5	0.56	0.75	0.79	0.35	0.9	-0.24	0.28	0.14	0.57	-0.33	0.31	0.37		0.38	-0.32	0.34	0.36
Net Debt	0.8	-0.27	0.88	0.84	0.49	-0.07	0.85	-0.36	0.95	0.59	0.42	0.57	0.5	0.25	0.13	0.98	0.22	0.16	0.29	0.88	0.99	0.38		-0.02	0.66	0.99
Cash And Short Term Investments	0.03	0.11	-0.17	-0.14	-0.21	-0.47	0.22	0.2	0.02	-0.34	-0.2	-0.11	-0.14	-0.4	0.96	0.04	-0.08	-0.3	-0.01	-0.18	0.06	-0.32	-0.02		0.15	0.0
Net Receivables	0.84	0.18	0.64	0.7	0.57	-0.18	0.61	-0.11	0.68	0.44	0.21	0.51	0.77	0.17	0.22	0.65	0.63	0.06	0.45	0.66	0.67	0.34	0.66	0.15		0.64
Non Current Liabilities Total	0.81	-0.23	0.89	0.86	0.53	-0.06	0.88	-0.34	0.94	0.57	0.41	0.54	0.52	0.24	0.16	0.99	0.26	0.14	0.33	0.89	0.98	0.36	0.99	0.0	0.64

Click cells to compare fundamentals

Calumet Specialty Account Relationship Matchups

Calumet Specialty fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.9B	1.8B	2.1B	2.7B	2.8B	1.8B
Total Stockholder Equity	(10.6M)	(12.3M)	(10.1M)	(287.7M)	(491.6M)	(467.0M)
Property Plant And Equipment Net	1.1B	1.0B	1.1B	1.6B	1.6B	934.6M
Non Current Assets Total	1.3B	1.3B	1.5B	1.9B	2.0B	1.2B
Non Currrent Assets Other	36.5M	37.2M	169.1M	122.6M	134.4M	141.1M
Other Assets	36.5M	37.2M	169.1M	122.6M	110.3M	59.0M
Common Stock Shares Outstanding	78.2M	78.4M	79.0M	79.3M	80.1M	52.4M
Liabilities And Stockholders Equity	1.8B	1.9B	2.5B	2.7B	2.8B	1.8B
Other Stockholder Equity	(20.2M)	125.3M	378.8M	(279.4M)	(484.4M)	(460.2M)
Total Liab	1.8B	1.9B	2.5B	3.0B	3.0B	1.5B
Property Plant And Equipment Gross	1.1B	1.0B	1.1B	1.6B	2.7B	2.9B
Other Current Liab	192.9M	212.6M	341.7M	587.3M	645.9M	678.2M
Total Current Liabilities	565M	544.5M	899.8M	1.4B	1.1B	1.2B
Accounts Payable	230.2M	179.3M	301M	442M	322M	239.3M
Other Liab	28.7M	28.2M	101.3M	100.6M	115.7M	121.5M
Cash	19.1M	109.4M	38.1M	35.2M	7.9M	7.5M
Long Term Debt	1.2B	1.3B	1.4B	1.5B	1.8B	1.1B
Inventory	292.6M	254.9M	326.6M	498M	439.4M	324.2M
Intangible Assets	71.2M	57.6M	45.8M	36.3M	28.5M	27.1M
Property Plant Equipment	973.5M	919.8M	1.1B	1.5B	1.7B	960.9M
Short Long Term Debt Total	1.3B	1.4B	1.6B	1.7B	2.2B	1.2B
Current Deferred Revenue	79.5M	68.8M	333.1M	190.4M	219.0M	229.9M
Net Debt	1.3B	1.3B	1.5B	1.6B	2.0B	1.1B
Cash And Short Term Investments	19.1M	109.4M	38.1M	35.2M	7.9M	7.5M
Net Receivables	188.5M	160.4M	253M	244.7M	286.2M	218.0M
Non Current Liabilities Total	1.3B	1.4B	1.6B	1.7B	1.9B	1.2B
Total Current Assets	512.1M	534.9M	632.6M	820.4M	794.7M	650.2M
Accumulated Other Comprehensive Income	(7.2M)	(8.7M)	(10.6M)	(12.3M)	(10.1M)	(6.8M)
Short Term Debt	62.4M	143.1M	245.5M	312.1M	131.3M	75.3M
Net Tangible Assets	(221M)	(359.2M)	(607.7M)	(497M)	(447.3M)	(424.9M)
Long Term Debt Total	1.2B	1.3B	1.4B	1.5B	1.8B	1.5B
Deferred Long Term Liab	31.7M	34.2M	82.3M	119.7M	137.7M	144.5M
Non Current Liabilities Other	61.7M	73M	15.8M	137.7M	10.4M	9.9M
Common Stock	20.2M	(125.3M)	(378.8M)	(529.9M)	(476.9M)	(453.1M)
Short Long Term Debt	1.5M	2.3M	7.4M	19.1M	55.7M	36.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Calumet Stock Analysis

When running Calumet Specialty's price analysis, check to measure Calumet Specialty's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calumet Specialty is operating at the current time. Most of Calumet Specialty's value examination focuses on studying past and present price action to predict the probability of Calumet Specialty's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calumet Specialty's price. Additionally, you may evaluate how the addition of Calumet Specialty to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC